Inflammatory bowel disease (IBD) is a multifactoral disease caused by dysregulated immune responses to commensal or pathogenic microbes in the intestine, resulting in chronic intestinal inflammation. An emerging population of patients with IBD younger than 5 years of age represent a unique form of disease, termed very early onset IBD (VEO-IBD), which is phenotypically and genetically distinct from older-onset IBD. VEO-IBD is associated with increased disease severity, aggressive progression, and poor responsiveness to most conventional therapies. Further investigation into the causes and pathogenesis of VEO-IBD will help improve treatment strategies and may lead to a better understanding of the mechanisms that are essential to maintain intestinal health or provoke the development of targeted therapeutic strategies to limit intestinal inflammation and promote tissue repair. Here, we discuss the phenotypic nature of VEO-IBD, the recent identification of novel gene variants associated with disease, and functional immunologic studies interrogating the contribution of specific genetic variants to the development of chronic intestinal inflammation. I nflammatory bowel disease (IBD), comprising Crohn's disease, ulcerative colitis, and indeterminate colitis, is a multigenetic and environmentally triggered disease resulting in a dysregulated immune response to commensal or pathogenic microbes found in the gastrointestinal tract. [1] [2] [3] [4] [5] [6] [7] Patients with IBD exhibit local and systemic immune reactivity to various microbes, have significant alterations in the composition of intestinal commensal bacteria, and can become colonized with pathogenic or opportunistic bacteria. [8] [9] [10] [11] [12] [13] [14] [15] The multifactorial nature and environmental contribution to IBD is largely responsible for its increased incidence over the last several decades. 16 Added to the complex nature of the disease, host genetics may play a more prominent role in some subpopulations, particularly in very young children (younger than 5 years of age) in whom the disease is termed very early-onset IBD (VEO-IBD). 17, 18 Although this is a heterogeneous population, including some children with mild disease, 19 patients with VEO-IBD can present with a different disease phenotype, including extensive colonic involvement and more severe disease than older children and adults. 17, 20, 21 In addition, due to poor response to conventional therapies, severity of inflammation, and greater duration of disease, there are higher rates of morbidity in this population. 20, 22, 23 Because of the aggressive disease phenotype, early age of onset, and strong family history of disease, some measure of VEO-IBD is thought to be a monogenic disease, often involving genes associated with primary immunodeficiencies.
patients with VEO-IBD. 20, 24 These include, but are not limited to, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome (WAS), immunodysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX) syndrome, and chronic granulomatous disease (CGD). 17, 20, 22, 26 Studying consanguinity and targeted genetic sequencing has been an extremely valuable approach to allow the identification and characterization of genetic variants associated with VEO-IBD. However, these approaches alone may not identify novel and rare gene variants. Recent advances in sequencing technology such as whole exome sequencing (WES) have broadened our understanding of the pathogenesis of VEO-IBD and resulted in further discoveries of genes and pathways associated with the disease. [26] [27] [28] [29] [30] The genomic contribution of IBD has been extensively evaluated through genomewide association studies (GWAS), and over 163 IBD-associated risk loci 31 have been identified. Several genes located within the IBD-associated loci are critical for regulation of host defense, involving both the innate and adaptive immune responses toward microbes. 31 However, GWAS studies have been primarily performed in adultonset IBD and in children 10 years of age and older, whose disease is most frequently a polygenic complex disease. Furthermore, GWAS often do not capture rare variants, specifically those with a minor allele frequency of <5%. In contrast, a proportion of patients with VEO-IBD have a monogenic-driven disease or multigenic disease enriched with rare variants of the same or interacting immunologic pathways. 32, 23 Thus, as in the case of IL10RA and IL10RB defects, the development of intestinal inflammation in VEO-IBD patients can be the direct result of defective immune responses. 33 Although WES has revolutionized our ability to study rare variants and to determine the genetic basis of disease, understanding the relevance of the identified variants has remained challenging. The individual patient's phenotype may be shaped by mode of inheritance, epigenetics, and gene-gene interaction. Environmental modifiers such as the intestinal microbiota, antibiotic exposure, infection, or diet also significantly impact the disease phenotype. 17, 26, 32 Because of the clinical presentation, often of severe disease, together with the challenge of identifying the unique pathogenesis of the disease, there is currently no standard of care in the evaluation and treatment for VEO-IBD patients. Identifying the driving forces in patients with particularly severe early-onset disease may lead to groupspecific therapeutic approaches. Here we discuss the clinical presentation of VEO-IBD patients, the identification of common gene variants associated with the disease, and functional studies that have demonstrated how these variants may contribute to dysregulated immunologic homeostasis in the intestine.
Clinical Presentation of Very Early Onset Inflammatory Bowel Disease
Pediatric IBD has increased in incidence and prevalence, and this phenomenon has included very young children. 16, 33, 34 VEO-IBD remains relatively uncommon, approximately 6% to 15% of the pediatric IBD population is younger than 6 years old, and disease in the first year of life is rare. 16, 34 A subset of patients with VEO-IBD present with a phenotype that is distinct from older children and adults, including extensive colonic disease (pancolitis) in which it is frequently difficult to differentiate ulcerative colitis from Crohn's disease, leading to a diagnosis of indeterminate colitis (Table 1) . 20, 34 At diagnosis, patients with VEO-IBD are more commonly diagnosed with ulcerative colitis (35% to 59%) as compared to older onset IBD (children older than 6 years and adults) in which Crohn's disease is more prevalent (55% to 60%). In contrast, approximately 30% to 35% of VEO-IBD patients are diagnosed with Crohn's disease. Indeterminate colitis is also diagnosed more often in patients with VEO (11% to 22%) as compared to older onset IBD (4% to 10%). 19, [35] [36] [37] Although formal guidelines or standards of care do not exist, disease evaluation of this population includes laboratory, radiologic, and endoscopic evaluation ( Table 2) . A diagnosis at a very young age should trigger concern for a monogenic-driven disease, particularly in IBD diagnosed when the patient is younger than 2 years of age. Furthermore, extensive family history, including a history of disease in male family members (such as in X-linked disease) or a history of infection, skin disease, or autoimmunity can help guide the appropriate laboratory screening. The laboratory studies should include not only the routine screening used for IBD diagnosis but also an immunologic evaluation. This includes vaccine titers, immunoglobulin profiles, analyses of B-and T-cell function, and a dihydrorhodamine flow cytometry assay, and if necessary more targeted phenotyping and functional profiling of the systemic and mucosal immune system. As shown in Table 2 , these studies may point to an underlying defect such as neutropenia, which may represent a monogenic disorder causing functional defects in neutrophils such as glycogen storage disease type 1b, leucocyte adhesion deficiency, or congenital neutropenia.
Genetic Variants Associated With VEO-IBD and Their Immunologic Consequences
Monogenic diseases that can present with the phenotype of intestinal inflammation include those that cause defects of intestinal epithelial barrier function, phagocyte bacterial killing, development and function of the adaptive immune system, and hyper-or autoimmune-inflammatory disorders. 32 These genetic alterations may differentially influence the development and progression of intestinal inflammation, so these patients will likely exhibit significant heterogeneity in their responsiveness to therapeutic interventions. We will discuss what we have learned from mouse models and translational patient-based studies, which should be considered when developing therapeutic strategies for these unique patient populations.
Genetic Variants Influencing Intestinal Epithelial Barrier Function
Mutations in genes associated with maintaining integrity of the intestinal epithelial barrier can present with intestinal inflammation in patients with VEO-IBD. These include lossof-function mutations in ADAM17 (A disintegrin and metalloproteinase domain 17) resulting in ADAM17 deficiency, 57, 58 in IKBKG (inhibitor of k light polypeptide gene enhancer in B cells, kinase of, g; encoding nuclear factor-kB essential modulator: NEMO) resulting in X-linked ectodermal dysplasia and immunodeficiency, 59 in COL7A1 (collagen, type VII, a1) resulting in dystrophic epidermolysis bullosa, 60 FERMT1 (Fermitin family homolog 1) resulting in Kindler syndrome, [61] [62] [63] and TTC7A (tetratricopeptide repeat domain-containing protein 7A, 29 or gain-of-function mutations in GUCY2 (guanylate cyclase 2) resulting in familial diarrhea. 17, 64 Mutations in these genes may all lead to an impairment of the intestinal epithelial barrier through distinct pathways, such as limiting epithelial regeneration (ADAM17), 65 loss of signaling pathways involved in gene expression (IKBKG), 66, 67 altered cell adhesion, barrier formation, apoptosis (COL7A1, FEMT1, and TTC7A), 29, [60] [61] [62] [63] or impaired bacterial sensing and ion homeostasis (GUCY2). 17, 64 The intestinal histology of patients with epithelial defects can be helpful in distinguishing the disease from other causes of intestinal inflammation. For example, patients with IKBKG (NEMO) defects may have villous atrophy or epithelial cell shedding on pathologic examination. 68 In contrast, histology in patients with ADAM17 mutations may demonstrate hypoplastic crypts in the small bowel secondary to a low rate of epithelial production, as ADAM17 is necessary for transforming growth factor-a to be cleaved from the cell membrane. 69, 70 The intestinal barrier is necessary to maintain a physical separation between commensal bacteria and the mammalian immune system, and a breakdown in this barrier through multiple distinct pathways can directly promote chronic intestinal inflammation. 1, 3 In addition to the genes we have listed, intestinal barrier function is maintained through a number of physical and biochemical structures, including mucus production, intestinal epithelial cell tight junction proteins, immunoglobulin A (IgA), and antimicrobial peptides (Figure 1 ). In mice, chemical disruption of the intestinal barrier through administration of dextran sodium sulfate in drinking water results in dissemination of commensal bacteria and activation of the innate immune system. 71 Chronic exposure to dextran sodium sulfate can lead to activation of the adaptive immune system and to the development of proinflammatory, commensal bacteriaspecific B-and T-cell responses, 8, 72 which are similar to those observed in IBD patients. 8, 73 Intestinal epithelial cells play an important role in directly regulating immunologic homeostasis in the intestine, as mice with intestinal epithelial cell lineage-specific deletion of factors regulating the nuclear factor-kB pathway, including NEMO and IkB kinase-b, have an increased susceptibility to develop chronic intestinal inflammation. 66, 67 Although we know that loss of intestinal barrier function can directly cause intestinal inflammation, additional mouse models and translational patient-based approaches are required to further define how mutations in these genes specifically lead to a breakdown in the barrier, and whether we can develop more targeted therapies to restore barrier integrity and limit chronic inflammation.
Genetic Variants Impairing Development of the Adaptive Immune System
Several genetic variants can alter the development or function of adaptive immune cells in a cell intrinsic or extrinsic manner. 32 Defects that affect development or function of B cells and T cells occur with loss-of-function mutations in recombination-activating genes (RAG1 or RAG2) or the IL-7R (IL7R) causing Omenn syndrome, or the PTEN (phosphatase and tensin homolog) gene causing PTEN syndrome. Defects in RAG1, RAG2, or IL-7R can cause cell-intrinsic defects in the development of both T cells and B cells by blocking either early lymphocyte survival or recombination of the B-cell receptor or T-cell receptor. [74] [75] [76] Defects in B-cell development lead to an absence of circulating mature B cells and antibody production, which have been linked to an IBD phenotype. 77 This includes agammaglobulinemia, which can also occur in X-linked agammaglobulinemia 78 and CVID, a complex and heterogeneous disease, with the responsible mutations known for only a minority of cases. 79 Recently, one candidate gene causing CVID and potentially contributing to intestinal inflammation was identified using WES as a loss-of-function mutation in LRBA (lipopolysaccharide-responsive beige-like anchor), resulting in multiple defects in immune cell populations. 40 Related to CVID, antibody deficiencies associated with IBD manifestations include IgA deficiency and severe combined immunodeficiency, which can be secondary to multiple variants that influence the development or function of the adaptive immune system (including RAG1, RAG2, JAK3, CD45, CD3G, ZAP70, ADA, DCLRE1C). 32, 77, 80 Omenn syndrome, a recessive form of severe combined immunodeficiency, involves abnormal development of B cells and T cells, and can also be associated with intestinal disease as well as severe eczematous rash. 80, 81 In these patients, laboratory studies indicate increased oligoclonal T cells and reduced B cells, and histologic examination can show an intestinal graft versus host appearance. 82, 83 Conversely, overproduction of specific immunoglobulins, such as hyper IgM, hyper IgE syndrome (resulting from a loss of function mutation in DOCK8) can also result in intestinal inflammation and an IBD phenotype. 84 It is currently unclear exactly how these selective impairments of the adaptive immune system can manifest in intestinal inflammation. There is a potential involvement of altered regulatory pathways or chronic infections with pathogenic and opportunistic microbes. Therefore, additional lines of study are required to further interrogate the link of these mutations to intestinal inflammation.
Wiskott-Aldrich syndrome results from a loss-offunction mutation in the Wiskott-Aldrich syndrome protein (WASP), and patients can exhibit thrombocytopenia, eczema, immune deficiencies, and intestinal inflammation. 85 The clinical manifestation of VEO-IBD patients with this genetic defect can be pancolitis in addition to other autoimmune processes. WASP is a critical cytoskeleton protein expressed in hematopoietic cells, and it is required for the normal development and function of multiple cell types. 86, 87 WASP is critical for peripheral Bcell development and function and thus the ability to respond to antigens. 88, 89 Laboratory studies in these patients may show thrombocytopenia, low IgM levels, low marginal B cells, and lymphopenia. 90 Nguyen et al 91 identified that intestinal inflammation in WASP-deficient mice was critically dependent upon inflammatory T cells, which may result from impaired development of regulatory T cells (Tregs) in the thymus and periphery. 92 Surprisingly, these defects are likely occurring in a cellextrinsic manner, as the absence of WASP in cells of the innate immune system directly contributed to the development of inflammatory T-cell responses in mice. 93 The causes of intestinal inflammation in other similar patient populations are less well understood, but defects in regulatory T cells, IgA, and abnormal selection of T-cell and B-cell specificities likely contribute. Additional immunologic analyses and mouse models, such as those we have described, are needed to define the causes of disease further and to develop potential therapeutic options in these patient populations.
Genetic Variants Impairing Regulatory T Cells
Defects in regulatory T cells can clinically present as colonic disease as well as an enteropathy. IPEX syndrome is most often secondary to mutations of the forkhead box protein 3 (FOXP3) gene, a transcription factor that is essential for the development and immunosuppressive activity of CD4 Foxp3 þ Tregs. 94, 95 There are over 20 mutations in FOXP3 that have been identified in patients with IPEX, 96 and patients frequently present with neonatal severe secretory diarrhea, failure to thrive, infection (due to defects in immunoregulation), skin rash, insulin-dependent diabetes, thyroiditis, cytopenias, and other autoimmune disorders. 94, 95 Tregs are absent or dysfunctional in these patients, and in the intestine histologic analyses may reveal infiltration of inflammatory cells in the lamina propria and submucosa of the small bowel and colon as well as changes in the mucosa of the small bowel. 94 Other genetic defects have been found to cause IPEX-like disease, including lossof-function mutations impacting IL-2/IL-2R interactions, STAT5b (signal transducer and activator of transcription 5b), and ITCH (itchy E3 ubiquitin protein ligase), or gainof-function mutations in STAT1, all of which critically influence the development and function of Tregs. 81 Further, Zeissig et al 97 have recently identified in VEO-IBD a novel loss of function mutation in CTLA4 (cytotoxic T lymphocyte-associated protein 4), a surface molecule of regulatory T cells that directly suppresses effector T-cell populations.
The mechanisms by which regulatory T cells limit intestinal inflammation are well characterized in mice. Tregs can develop in the thymus as "natural Tregs" and directly contribute to limiting proinflammatory T cells in the intestine. 98 The composition of commensal bacteria influences the repertoire of Tregs, 98 and commensal bacteria-specific "induced Tregs" can also be generated in the periphery after sampling of commensal bacteria by dendritic cells in the intestine and migration to the mesenteric lymph node (Figure 2) . 1,5,99,100 Once generated, Tregs can then promote intestinal homeostasis through direct regulation of innate and adaptive immune cell responses to commensal bacteria, a process that involves cytokine production, direct cell-cell contact (in part through CTLA4), and sequestering of growth factors. 1, 5, 99 Consistent with a major role for Tregs in limiting proinflammatory immune cell responses to commensal bacteria, mice deficient in IL-2 or FoxP3 develop significantly less intestinal inflammation when maintained in germ-free versus conventional housing conditions, but they exhibit comparable levels of systemic autoimmunity. 101, 102 Recent evidence also suggests that the balance of tissuespecific IL-23 and IL-33 expression in mice is critical for regulating the function of Tregs in the intestine and chronic inflammation, 103 although the role of these pathways in human VEO-IBD has not been examined. Figure 2 . Regulatory T cells, interleukin-10 (IL-10) and ILC3 critically limit dysregulated immune responses to commensal bacteria. Regulatory T cells (Treg) can differentiate in the thymus or periphery and limit immune cell responses to intestinal commensal bacteria through multiple mechanisms, including cytokine production, direct cell-to-cell contact and sequestering of growth factors. Further, IL-10 production by multiple cell types can directly promote anti-inflammatory responses from myeloid cells to limit intestinal inflammation. ILC3 can also directly limit proinflammatory T cells through MHCII-dependent interactions. iTreg, inducible regulatory T cell; nTreg, natural regulatory T cell. Identified genetic variants that result in a loss or gain of function mutation and are associated with very early onset inflammatory bowel disease are noted in orange boxes.
Genetic Variants in the Interleukin-10/Interleukin-10 Receptor Pathway and Related Cytokine Family Members
Homozygous loss of function mutations in IL10 ligand and receptors IL10RA and IL10RB are associated with significant intestinal inflammation, particularly in neonatal or infantile VEO-IBD, with a phenotype of severe enterocolitis and perianal disease. 23, 25 In addition, compound heterozygote loss of function mutations of IL10RA have been reported with neonatal Crohn's disease and enterocolitis. 105,106 IL-10 maintains homeostasis through suppression of an excessive proinflammatory response and exerts its effect through binding to the IL-10 receptor, IL-10R, which is a tetrameric complex. 107 It is composed of 2 distinct chains, 2 molecules of IL-10R1 (a chain) and 2 molecules of IL-10R2 (b chain).
108 IL-10 binding to IL-10R activates the JAK1/STAT3 cascade, which subsequently limits proinflammatory gene expression. 108 In addition to intestinal inflammation, IL-10 defects are associated with arthritis, folliculitis, and a predisposition to lymphoma. 104, 109 Given that the defects in IL-10-IL-10R interactions predominantly influence the immune system, a potential treatment for these patients is successful hematopoietic stem cell transplantation. 110 Although this can be challenging and typically requires an HLA-identical donor, there has been recent success reported with haploidentical stem cell transplantation, however nonengraftment complications can occur. 111 An essential role for IL-10 in limiting intestinal inflammation was demonstrated when IL-10 deficient mice were generated and found develop severe spontaneous colitis, 112 and subsequent studies by Sartor et al 113 identified that the intestinal inflammation in IL-10-deficient mice was entirely dependent upon the presence of commensal bacteria. Therefore, IL-10 plays a critical role in limiting dysregulated immune cell responses to intestinal commensal bacteria (Figure 2 ). The exact cellular sources and targets of IL-10 that contribute to the maintenance of intestinal homeostasis have been less well defined until the recent development of mice that permit conditional deletion of IL-10 and IL-10R. These critical studies have revealed an essential role of regulatory T cell-intrinsic IL-10 expression in preventing intestinal inflammation in mice. 114, 115 Further, it was recently demonstrated that IL-10R expression on myeloid cells in mice is critical to elicit anti-inflammatory responses and limit T cell-dependent intestinal inflammation. 116, 117 Critically, patients with loss-of-function mutations in IL10RA or IL10RB also exhibited an impaired ability to differentiate anti-inflammatory myeloid cells in vitro, and rather exhibited increased proinflammatory properties, such as elevated expression of IL-6, IL-12, tumor necrosis factor-a (TNFa), MHCII (major histocompatibility complex class II), and costimulatory molecules. 116 Although mouse models have provided invaluable insight into human health and disease, it should be noted that mice deficient in Il10 do not completely replicate the phenotypes of humans with loss-of-function mutations in IL10, likely due to many confounding factors.
IL-22 is a cytokine that is related to IL-10, shares the IL-10R2 chain with a unique IL-22R1, signals through predominantly STAT3, and also plays a critical role in mediating intestinal homeostasis. 118 However, unlike IL-10, the functional IL-22R is restricted to predominantly nonhematopoietic cells; in the intestine, IL-22 acts almost exclusively on intestinal epithelial cells to mediate innate immunity and intestinal barrier function (Figure 1) . 118 IL-22 can be produced by T H 17 cells, and more recently has been identified to be predominantly expressed by a previously unrecognized cell type of the innate immune system, termed group 3 innate lymphoid cells (ILC3). 118, 119 This breakthrough in immunology has led to the identification of other members of the innate lymphoid cell (ILC) family, including group 1 ILCs that express T-bet and proinflammatory cytokines TNFa and interferon-g, and group 2 ILCs that express GATA3 and type 2 cytokines IL-4, IL-5, IL-9, IL-13, and amphiregulin. 119, 120 The ILC family exhibits a heterogeneity comparable to that of differentiated CD4 T-cell subsets, and plays a profound role in regulating intestinal health and disease in mouse models. [118] [119] [120] Critically, recent reports suggest that ILC3 is a dominant source of IL-22 in the intestine of healthy humans, and that dysregulated ILC responses are observed in adult patients with IBD. [121] [122] [123] [124] [125] [126] [127] Further, we have also recently identified that ILC3 expresses MHCII, and that selective deletion of MHCII on ILC3 results in dysregulated CD4 T-cell responses and spontaneous intestinal inflammation. 122 
MHCII
þ ILC3 selectively induces cell death of proinflammatory, commensal bacteria-specific CD4 T cells in the intestine; critically, we observed that MHCII was reduced on ILC3 from intestinal biopsy tissues of pediatric IBD patients versus non-IBD controls, and that this was inversely correlated with the level of proinflammatory T H 17 cells. 128 Despite these advances, ILC and IL-22 responses have yet to be explored in VEO-IBD. Given the importance of these pathways in mediating intestinal health and disease, it is likely that the genetic variations associated with VEO-IBD, such as IL7/IL7R, may differentially influence ILC responses.
Genetic Variants Influencing Bacterial Recognition and Clearance
Chronic granulomatous disease (CGD) is a result of defective intestinal phagocytes, specifically the granulocytes responsible for bacterial killing and clearance. 129 The NADPH oxidase complex is responsible for killing ingested microbes through its production of the respiratory burst. Mutations in any part of the complex molecules (CYBB, CYBA, NCF1, NCF2, NCF4) can result in intestinal inflammation as well as autoimmune disease. 130, 131 Intestinal inflammation can be observed in as many as 40% of patients with CGD. 52, [132] [133] [134] Several variants have been associated with VEO-IBD, in particular defective NCF2 (neutrophil cytosolic factor 2) results in altered binding to RAC2 (ras-related C3 botulinum toxin substrate 2). 135 These patients can present in the neonatal or first year of life with colitis, severe fistulizing perianal disease, and stricturing. 135 Histology frequently demonstrates multiple granulomas that may not have associated inflammatory change. 26 Critically, a recent study by Dhillon et al 136 identified that heterozygous loss-offunction mutations in components of the NADPH oxidase complex can determine susceptibility to VEO-IBD, without directly causing overt immunodeficiency. Other neutrophil defects that are associated with VEO-IBD include leukocyteadhesion defect due to mutation in ITGB2 (integrin, b2). 137, 138 These patients can present with an IBD phenotype, history of bacterial infection, and laboratory studies remarkable for increased peripheral granulocytes. 139 Glycogen storage disease type 1b, with hallmark features of neutropenia and neutrophil granulocyte dysfunction, can present with intestinal inflammation. 140 The reasons why CGD and other bacterial processing defects may manifest in intestinal inflammation are poorly understood and warrant additional research. It is possible that the causes include bacterial overgrowth or dysbiosis in the intestine, dysregulated activation of the innate and adaptive immune system, or both.
Further, the therapies used to treat such patients need to be carefully considered. For example, anti-TNFa therapy is contraindicated in CGD; although it is effective for intestinal disease, it can increase the risk of severe infections in these patients. 141 Other therapies include leukine, antibiotics, and allogenic hematopoietic stem cell transplantation, which have demonstrated some success. 142 Recent evidence suggests that IL-1R antagonists may be a particularly attractive approach to limit disease in mouse models and patients with CGD by restoring autophagy and directly limiting inflammation. 143 Hyper-and Autoimmune-Disorders Several autoimmune diseases have been linked with intestinal inflammation in children with VEO-IBD. These include mevalonate-kinase deficiency, 144 familial Mediterranean fever (FMF), 145, 146 Hermansky-Pudlak syndrome, 147 and X-linked lymphoproliferative syndrome (types 1 and 2). 28, 148, 149 These diseases occur due to loss-of-function mutations in an enzyme critical for metabolism (mevalonatekinase deficiency), cytoskeletal proteins (familial Mediterranean fever), proteins involved in organelle fusion or biogenesis (Hermansky-Pudlak syndrome), or proteins involved in cell signaling or apoptosis (X-linked lymphoproliferative syndrome). Although there are many additional clinical manifestations in these patients, 20% of patients with X-linked lymphoproliferative syndrome that have a loss-of-function defect in the gene X-linked inhibitor of apoptosis protein (XIAP), present with VEO-IBD. 150 XIAP is involved in nucleotide-binding oligomerization domain-containing protein 2 (NOD2)-mediated nuclear factor-kB signaling, so these children may have an impaired ability to sense bacteria. In addition, as an inhibitor of apoptosis, it prevents apoptosis of activated T cells, thus allowing for expansion and survival of T cells in response to pathogens. 151, 152 Therefore, in XIAP deficiency, due to the inability to clear pathogens, there is a hyperinflammatory state with increased production of cytokines resulting in an IBD phenotype. 150, 152 Children with these mutations can present with severe colonic and perianal fistulizing disease; 28, 153 of great concern, Epstein-Barr virus infection can result in fatal hemophagocytic lymphohistiocytosis. 153 This was not an exhaustive description of the rare genomic drivers of VEO-IBD, but it highlights the different components of the immune system, including innate and adaptive responses, involved in this disease. Treatments guided toward the specific defect, such as IL-1 antagonists, colchicine, hematopoietic stem-cell transplantation, or leukine can be used if the defect is determined. Additionally, monitoring for potential complications associated with a genetic defect is essential, such as in XIAP, IL-10 gene variants, and CGD. In addition to these monogenic diseases, VEO-IBD has been shown to have a high degree of genetic heterogeneity. It is therefore likely that there are more pathways involved in VEO-IBD, and the outcome of therapeutic intervention can be improved through further study and identification of the associated variants. Using nextgeneration sequencing technology such as WES can improve the detection of variants and the diagnosis of disease. Further, there is an urgent need to also directly translate genes to function and to functionally profile the immunologic significance of known genetic variations in intestinal inflammation.
Perspective and Future Directions in Genetic and Immunologic Analyses of Very Early Onset Inflammatory Bowel Disease
To advance our understanding of VEO-IBD, new sequencing technology must be used to completely survey the genetic landscape of this disease. Immunologic studies spanning basic mouse models and translational patientbased approaches are required to determine the contribution of those genetic variations to human disease. Given that dysregulated interactions between the immune system and commensal bacteria underlie the pathogenesis of intestinal inflammation, it is also important to include analyses of the composition and function of the microbiome. Given that these patient populations are studied worldwide and sometimes in small numbers, an international registry containing the genetic, immunologic, and environmental data of VEO-IBD patients could prove beneficial in our goal of better understanding the effects of different variants within known genes and identifying new gene defects that cause IBD through the study of mutations that arise in the same genes of multiple unrelated individuals. With an increased understanding of the disease processes operating in VEO-IBD, we can begin to individualize therapies to the specific patient or patient groups, as well as employ unconventional therapies that are not routinely part of the IBD therapeutic arsenal. These approaches could provide a roadmap to establishing a standard of care for this disease and improving patient quality of life.
